



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/019,800	07/17/2002	David Greaves	PG3717	7658
20462	7590 07/01/2004		EXAMINER	
SMITHKLI	NE BEECHAM CORF	KELLY, ROBERT M		
	CORPORATE INTELLECTUAL PROPERTY-US, UW2220 P. O. BOX 1539			PAPER NUMBER
	RUSSIA, PA 19406-093	1632		

DATE MAILED: 07/01/2004

Please find below and/or attached an Office communication concerning this application or proceeding.



	Application No.	Applicant(s)				
	10/019,800	GREAVES ET AL.				
Office Action Summary	Examiner	Art Unit				
	Robert M Kelly	1632				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period volume to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	66(a). In no event, however, may a reply be ting within the statutory minimum of thirty (30) day will apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on <u>07 July 2003</u> .						
/						
	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
closed in accordance with the practice under E	ex parte Quayle, 1955 C.D. 11, 45	J3 Q.G. 213.				
Disposition of Claims						
 4) Claim(s) 1-20 is/are pending in the application 4a) Of the above claim(s) is/are withdray 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 1-20 are subject to restriction and/or 	wn from consideration.					
Application Papers						
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) acc Applicant may not request that any objection to the Replacement drawing sheet(s) including the correc 11) The oath or declaration is objected to by the Examine	epted or b) objected to by the drawing(s) be held in abeyance. Se tion is required if the drawing(s) is ob	e 37 CFR 1.85(a). ojected to. See 37 CFR 1.121(d).				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority document application from the International Burea * See the attached detailed Office action for a list	s have been received. s have been received in Applicative documents have been received in Receiver (PCT Rule 17.2(a)).	tion No red in this National Stage				
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summar Paper No(s)/Mail D 5) Notice of Informal 6) Other:					

Art Unit: 1632

DETAILED ACTION

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1, 6, and 8, 11-12, 15, and 18-20, drawn to a DNA construct comprising a transcriptional regulatory sequence operably linked to a heterologous gene of interest, pharmaceutical compositions, and a method of treating a disease.

Group II, claim(s) 2-4, 7, and 17 drawn to a DNA construct comprising a transcriptional regulatory sequence operably linked to a heterologous gene of interest and further comprising at least one eIF4A intron with transcriptional regulatory function, fragment thereof, or polynucleotide that hybridizes to the intron retaining its transcriptional regulatory function.

Group III, claim(s) 5, drawn to a DNA construct comprising a transcriptional regulatory sequence operably linked to a heterologous gene of interest and further comprising at least two eIF4A introns with transcriptional regulatory function, fragment thereof, or polynucleotide that hybridizes to the intron retaining its transcriptional regulatory function.

Group IV, claim(s) 9-10, drawn to a host cell comprising a nucleic acid sequence and a process of producing a protein.

The inventions listed as Groups I-IV do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The special technical feature shared by groups I-II is a DNA construct comprising an eIF4A promoter operably linked to a heterologous gene. Kukimoto, et al. (1997) Biochem. Biophys. Res. Comms. 233: 844-47 (provided in Applicant's information disclosure statement of 4 January 2002) discloses eIF4A promoter linked to a heterologous gene, the Luc gene (See Figure 2A). Therefore, there is no special technical feature contributed by the present invention over the prior art regarding groups I-II. Moreover, the special technical feature of group II further comprises an intron, group III further comprises a second intron, group IV

Art Unit: 1632

comprises a host cell that produces a protein. Each of these additional features require different structural and functional considerations that are not coextensive with any other group. For example, while group I requires a promoter and heterologous gene, group II requires consideration of an intron to further effect transcription, group III requires a consideration of a second intron to effect transcription, and group IV requires a consideration of the processes through a host cell can produce a protein. As set forth, these special technical features are not required of the other groups. Thus, Groups I-IV do not relate to a single general inventive concept under PCT Rule 13.1.

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows:

Applicant is required to elect one intron of Claim 3; and a corresponding SEQ ID NO of Claims 7 and 17.

Applicant is required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

The claims are deemed to correspond to the species listed above in the following manner:

Each election is required for groups II.

Art Unit: 1632

The following claim(s) are generic: 2.

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: each of these introns, and their corresponding SEQ ID NOs have different sequences, with different structure, and therefore, different function. Moreover, the search and examination of any two of sequences together would pose an undue burden on the examiner.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert M Kelly whose telephone number is (571) 272-0729. The examiner can normally be reached on M-F, 9:00am-5:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Amy Nelson can be reached on (571) 272-0804. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Art Unit: 1632

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

RAM R. SHUKLA, PH.D. BRIMARY EXAMINER